Welcome to our dedicated page for Sangamo Therapeutics SEC filings (Ticker: SGMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sangamo Therapeutics, Inc. (SGMO) SEC filings page on Stock Titan provides direct access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI‑generated summaries that help explain their contents. Sangamo is a genomic medicine company listed on the Nasdaq Capital Market, and its filings document clinical, regulatory, financial and listing‑related developments across its Fabry disease and neurology‑focused pipeline.
Investors can review Sangamo’s current reports on Form 8‑K, which the company uses to report material events. Recent 8‑Ks describe positive topline and updated data from the registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST‑920) in Fabry disease, including mean annualized estimated glomerular filtration rate (eGFR) slopes and safety findings, as well as the FDA’s agreement to use eGFR slope as an endpoint for an accelerated approval pathway. Other 8‑Ks cover quarterly financial results, collaboration and license agreements, executive transitions and a Nasdaq notice granting additional time to regain compliance with the minimum bid price requirement.
Annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available in the feed) provide more detailed information on Sangamo’s research and development expenses, general and administrative costs, cash and cash equivalents, and risk factors related to its genomic medicine programs, collaborations and capital needs. These filings also elaborate on the company’s description of its business as a neurology‑focused genomic medicine company and its reliance on investigational product candidates such as ST‑920, ST‑503 and ST‑506.
On this page, Stock Titan’s tools surface new SGMO filings from EDGAR in near real time and apply AI‑powered analysis to highlight key points, such as clinical endpoints referenced in 8‑Ks, updates on BLA preparation activities, or disclosures about Nasdaq listing compliance. Users can also locate proxy statements and other governance‑related documents to better understand Sangamo’s executive compensation plans and board‑level decisions, as referenced in its SEC filings. This combination of source documents and AI summaries is intended to make it easier to interpret complex regulatory language without replacing the need to read the original filings.
Sangamo Therapeutics senior executive reports share dispositions tied to RSU tax withholding. SVP and Chief Development Officer Nathalie Dubois-Stringfellow surrendered 2,063 common shares at
Both transactions were required to cover taxes on restricted stock units that had just vested under the company’s 2018 Equity Incentive Plan and were deemed dispositions to the company, not discretionary open‑market trades. After these transactions, she directly owns 678,711 common shares.
Sangamo Therapeutics President and CEO Sandy Macrae reported two required tax-withholding dispositions of common stock tied to vested restricted stock units. On February 24, 2026, 5,291 shares were surrendered at
Sangamo Therapeutics SVP and Chief Legal Officer Scott B. Willoughby reported mandatory tax-withholding share dispositions tied to restricted stock unit (RSU) vesting. On February 24, 2026, 1,650 common shares were surrendered at $0.4725 per share, and on February 25, 2026, 12,354 common shares were surrendered at $0.47 per share.
In both cases, the shares were delivered back to the company solely to cover tax liabilities upon RSU vesting under Sangamo’s 2018 Equity Incentive Plan and were not discretionary open-market trades. After these transactions, Willoughby directly owned 651,406 shares of Sangamo common stock.
Sangamo Therapeutics principal accounting officer Nikunj Jain reported two share dispositions tied to restricted stock unit (RSU) vesting and tax withholding. On February 24, 2026, 666 shares of common stock were surrendered at $0.4725 per share to satisfy mandatory tax obligations on vested RSUs.
On February 25, 2026, an additional 5,119 shares were surrendered at $0.47 per share for the same tax-withholding purpose under the company’s 2018 Equity Incentive Plan. These transactions are reported as dispositions to the company and are explicitly described as non-discretionary, not open-market trades.
Sangamo Therapeutics Head of Research & Technology Gregory D. Davis reported mandatory tax-related share dispositions tied to vesting restricted stock units. On February 24, 2026, 832 shares of common stock were surrendered at
Sangamo Therapeutics, Inc. entered into an underwritten public offering of 35,190,292 shares of common stock and pre-funded warrants for 17,787,033 shares, each paired with purchase warrants to buy a total of 52,977,325 shares. The combined offering prices are $0.4719 per common-share unit and $0.4619 per pre-funded warrant unit, with expected gross proceeds of approximately $25.0 million before fees, and closing expected on February 4, 2026, subject to customary conditions.
The pre-funded warrants are immediately exercisable at $0.01 per share with ownership caps up to 19.99%, while the purchase warrants become exercisable six months after issuance at $0.4719 per share for five and a half years, subject to a 4.99% ownership cap that can also be increased to 19.99%. In connection with the deal, Sangamo amended March 26, 2024 warrants held by the investor to reduce the exercise price on 23,809,523 shares from $1.00 to $0.4719 and extend their term to five and a half years from the offering’s closing.
Sangamo Therapeutics is offering 35,190,292 shares of common stock, pre-funded warrants for 17,787,033 shares, and purchase warrants for 52,977,325 shares. Securities are priced at $0.4719 per share and accompanying purchase warrant (or $0.4619 for a pre-funded warrant plus purchase warrant), yielding gross proceeds of about $24.8 million and estimated net proceeds of about $22.9 million before any warrant exercises.
The company plans to use the cash for working capital and general corporate purposes. Sangamo estimates cash and cash equivalents of approximately $20.9 million as of December 31, 2025 and, together with $2.0 million from its at-the-market program and this offering, expects funding only into the beginning of the third quarter of 2026.
The filing states there is substantial doubt about Sangamo’s ability to continue as a going concern even after this raise and notes active consideration of significant cost cuts and potential bankruptcy protection if additional capital or partnerships are not secured. The company also faces Nasdaq delisting risk due to its share price remaining below the $1.00 minimum bid requirement, with an extension to regain compliance by April 27, 2026.
Sangamo Therapeutics reported detailed Phase 1/2 STAAR data for its Fabry disease gene therapy isaralgagene civaparvovec (ST-920) and a clear U.S. regulatory path. The FDA agreed that this single Phase 1/2 study can serve as the primary basis for Accelerated Approval, using mean annualized eGFR slope at 52 weeks as the key endpoint.
The study treated 33 adults with a one-time infusion and showed a generally well-tolerated safety profile, with no deaths, no thrombotic microangiopathy or complement activation, and mostly mild or moderate adverse events. All 18 patients who entered on enzyme replacement therapy were able to stop ERT after dosing, while enzyme activity, kidney function slopes, cardiac measures, quality of life, gastrointestinal symptoms, and Fabry disease severity scores remained stable or improved over follow-up, supporting the ongoing rolling BLA submission.
Sangamo Therapeutics, Inc. reported a preliminary estimate that its cash and cash equivalents were approximately $20.9 million as of December 31, 2025. This figure is unaudited, subject to change, and may be adjusted when the audited financial statements for 2025 are completed.
The company also disclosed a leadership change in its finance team. On February 2, 2026, the employment of Prathyusha Duraibabu, the principal financial officer, terminated. Effective February 3, 2026, Nikunj Jain, Vice President, Finance and Corporate Controller and principal accounting officer, was appointed Interim Chief Financial Officer and will serve as the principal financial officer without additional compensation.
Sangamo Therapeutics’ Principal Accounting Officer, Nikunj Jain, reported an automatic share withholding tied to restricted stock units. On January 22, 2026, 7,721 shares of common stock underlying a vested RSU tranche were surrendered back to Sangamo at $0.3985 per share to cover mandatory tax withholding under the company’s 2018 Equity Incentive Plan. This is treated as a disposition for reporting purposes but is not a discretionary open-market trade.
After this tax withholding event, Jain beneficially owned 242,996 shares, including RSUs from grants dated February 24, 2023, January 22, 2024, and February 25, 2025 that vest over time, as well as 5,000 shares acquired under the 2020 Employee Stock Purchase Plan.